跳至主要内容
临床试验/ACTRN12612000465853
ACTRN12612000465853尚未招募1 期

Safety and Immunogenicity of Sabin-IPV and adjuvanted Sabin-IPV in healthy adults

World Health Organization0 个研究点目标入组 30 人开始时间: 2012年4月27日最近更新:

试验速览

阶段
1 期
状态
尚未招募
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Prevention
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 24 Years(—)
性别
Male

入选标准

  • Subjects must fulfill all of the following criteria:
  • - University student attending the Faculty of Chemistry and Pharmacology, Camaguey University, Camaguey
  • - Age 18 to 24, inclusive at the time of enrollment
  • - In good health as determined by the outcome of medical history, physical examination screening/baseline labs, and clinical judgment of the investigator
  • - Must have received polio vaccinations with OPV according to the Cuban National Immunization Program as a child
  • - Preferred: number (and date) of polio vaccinations known
  • - Willingness and ability to adhere to the study regimen
  • - Having a signed informed consent form

排除标准

  • Temporary exclusion criteria for vaccination:
  • - If body temperature >=38C this will lead to postponement of participation and vaccination. Screening may continue when the temperature has normalized.
  • The exclusion criteria for vaccination are:
  • - IPV or OPV booster dose after the age of 12 years
  • - Known or suspected allergy against any of the vaccine components
  • - History of unusual or severe reactions to any previous vaccination
  • - Known or suspected disease or use of medication that may influence the immune system
  • - Known or suspected immune deficiency
  • - Systemic treatment with corticosteroids within one month before screening
  • - Administration of plasma (including immunoglobulins) or blood products three months prior to the study
  • - Blood donation within one month before screening
  • - Any vaccination within three months before screening and during the study until the last visit
  • - History of any neurological disorder including epilepsy or febrile seizures
  • - Evidence of excessive alcohol use or drug use
  • - Any infectious disease
  • - Participation in another clinical trial within three months before screening
  • - Abnormal pre-treatment laboratory parameters which are clinically relevant according to the investigator
  • The exclusion criteria for blood collections are:
  • - Bleeding disorders or the usage of anticoagulants

研究者

相似试验